Listed

American Vanguard Corp: Form 10-Q for the period ended Sep 30, 2019

Filed with the SEC on Nov 6, 2019 and accepted by EDGAR at Nov 6, 2019, 16:51 ET.

Share

Management's discussion and analysis

As filed, 43,205 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

FORWARD-LOOKING STATEMENTS/RISK FACTORS:

The Company, from time-to-time, may discuss forward-looking statements including assumptions concerning the Company’s operations, future results and prospects. These forward-looking statements are based on current expectations and are subject to a number of risks, uncertainties and other factors. In connection with the Private Securities Litigation Reform Act of 1995, the Company provides the following cautionary statements identifying important factors which, among other things, could cause the actual results and events to differ materially from those set forth in or implied by the forward-looking statements and related assumptions contained in the entire Report. Such factors include, but are not limited to: product demand and market acceptance risks; the effect of economic conditions; weather conditions; changes in regulatory policy; the impact of competitive products and pricing; changes in foreign exchange rates; product development and commercialization difficulties; capacity and supply constraints or difficulties; availability of capital resources; general business regulations, including taxes and other risks as detailed from time-to-time in the Company’s reports filed with the US Securities and Exchange Commission (the “SEC”). It is not possible to foresee or identify all such factors. For more detailed information, refer to Item 1A, Risk factors and Item 7A, Quantitative and Qualitative Disclosures about Market Risk, in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 as well as in the Company’s Form 10-Q for the period ended September 30, 2019.

MANAGEMENT OVERVIEW

The Company’s top line showed growth during the third quarter of 2019, led by our international businesses, which recorded a 27% increase in net sales, a 36% increase in gross profit and improved profit margins. During the period, the domestic business generated a 3% increase in net sales, while posting a 5% decrease in gross profit and a decline in gross margin percentage. Our international business continued to grow as a percent of the global enterprise, accounting for 41% of total net sales during the quarter, which is up from 36% in 2018. Improved performance in Central America, Mexico and Brazil (as a result of businesses acquired earlier in 2019) led our international growth. By contrast, expansion of our domestic business was largely constrained by the effects of severe weather. The wet and cold conditions of the 2019 planting season served to reduce demand for both fumigants and burn-down herbicides post-plant, while record-setting heat in the southern US during the third quarter reduced demand for our cotton defoliant, Folex.

In spite of overall growth, the Company’s profitability declined during the three months ended September 30, 2019. This was due primarily to the following factors. First, quarterly gross margins dropped from 41% to 38%, arising largely from both comparatively higher sales of lower-margin international products and lower factory utilization during the period, as the Company endeavored to limit production reflecting weather related comparatively softer demand for certain product lines, in order to overall inventory levels. Second, operating expenses for the period rose by 21% primarily due to operating expenses and amortization costs for new businesses, increased selling expenses (from marketing and promotional efforts in our domestic markets) and a comparatively higher benefit for the reassessment of deferred purchase price consideration in the third quarter of 2018. Third, the Company incurred higher interest expense during the period, due to higher average indebtedness arising from product acquisitions that occurred since the comparable period in 2018. These factors, taken together, yielded a decrease in net income attributable to American Vanguard for the quarter.

Quarterly net sales were up over 12% ($124,884 vs. $111,780), and gross profit rose approximately 5% ($47,463 vs. $45,300). Gross margin declined to 38% from 41% of net sales, while operating expenses rose by approximately 21% ($40,677 vs. $33,635), increasing as a percent of net sales from 30% to 33%. Net income attributable to American Vanguard was down 52% ($3,153 vs. $6,525).

The Company’s overview of sales and gross margin performance for the three months ended September 30, 2019 and 2018 is as follows:

Net sales: For the three months ended September 30, 2019 2018 Change % Change
US crop $55,952 $55,285 $667 1%
US non-crop 18,036 16,426 1,610 10%
US total 73,988 71,711 2,277 3%
International 50,896 40,069 10,827 27%
Net sales: $124,884 $111,780 $13,104 12%
Gross profit:
US crop $23,926 $27,106 $(3,180) -12%
US non-crop 9,491 7,991 1,500 19%
US total 33,417 35,097 (1,680) -5%
International 14,046 10,203 3,843 38%
Total gross profit: $47,463 $45,300 $2,163 5%
Gross margin domestic 45% 49%
Gross margin international 28% 25%
Gross margin total 38% 41%

Our domestic business grew slightly during the third quarter of 2019 with sales up 3% versus those of the same period in 2018. Within quarterly domestic sales, our US Crop business recorded 1% higher sales, while our US non-crop business grew its top line by 10% quarter over quarter. Growth of the US Crop business was primarily limited by record heat and dryness in the Southern region, which reduced the need for Folex. By contrast, within the US non-crop business, hurricane and storm activity spurred increased sales of our mosquito products.

Within our US Crop business, sales performance was mixed. We experienced strong demand for Aztec corn soil insecticide, Counter nematicide and Bidrin foliar cotton insecticide. Demand was also up for herbicides, Dacthal, which is used on high-value vegetable crops, and Parazone products, which are used for burn down applications. Our soil fumigant business was flat, in spite of wet late season weather in parts of the country, while our fungicide business benefitted from stronger demand for our Equus® and PCNB products. The most significant negative factor in the US Crop business during the quarter was, as mentioned above, the record-setting, extreme heat and dryness which affected demand for our Folex®, sales of which decreased approximately $10,000 in the period.

Net sales of our US non-crop business increased about 10% to $18,036 from $16,426, quarter-over-quarter. This result was due largely to increased sales of our aerially-applied mosquito adulticide, Dibrom®, as applicators restocked to address persistent wet weather conditions in the US and to prepare for potential hurricane activity later in 2019.

Net sales of our international businesses were up 27% during the period ($50,896 vs. $40,069). A significant part of this increase was due to the addition of sales from our newly acquired Brazilian and Australian subsidiaries, and the addition of our Assure II herbicide products that were acquired in December 2018. We experienced improved sales performance from AgriCenter in Central America, despite some temporary usage declines in bananas, pineapples and citrus resulting from drought, and seasonal crop rotation in bananas that reduced nematicide applications in 2019 (that are expected to increase in 2020). Elsewhere in the international business, we posted decreased sales of Mocap insecticide (in light of the phase-out of that product in the EU associated with non-renewal of its registration) and bromacil herbicides (due to continuing supply shortages) during this period. Both Nemacur and Thimet posted small sales declines outside of the US, primarily as the result of various weather-related issues. A more detailed explanation of net sales, markets and factors affecting profitability appears below.

RESULTS OF OPERATIONS

Quarter Ended September 30, 2019 and 2018:

Net sales: 2019 2018 Change % Change
Insecticides $35,847 $31,048 $4,799 15%
Herbicides/soil fumigants/fungicides 46,772 41,882 4,890 12%
Other, including plant growth regulators 22,887 22,424 463 2%
Total crop 105,506 95,354 10,152 11%
Non-crop 19,378 16,426 2,952 18%
Total net sales $124,884 $111,780 $13,104 12%
Cost of sales:
Insecticides $23,071 $20,940 $2,131 10%
Herbicides/soil fumigants/fungicides 29,414 24,814 4,600 19%
Other, including plant growth regulators 15,648 12,291 3,357 27%
Total crop 68,133 58,045 10,088 17%
Non-crop 9,288 8,435 853 10%
Total cost of sales $77,421 $66,480 $10,941 16%
Gross profit:
Insecticides $12,776 $10,108 $2,668 26%
Herbicides/soil fumigants/fungicides 17,358 17,068 290 2%
Other, including plant growth regulators 7,239 10,133 (2,894) -29%
Gross profit crop 37,373 37,309 64 0%
Gross profit non-crop 10,090 7,991 2,099 26%
Total gross profit $47,463 $45,300 $2,163 5%
Gross margin crop 35% 39%
Gross margin non-crop 52% 49%
Total gross margin 38% 41%
Net sales: 2019 2018 Change % Change
US $73,988 $71,711 $2,277 3%
International 50,896 40,069 10,827 27%
Net sales: $124,884 $111,780 $13,104 12%

For the three months ended September 30, 2019, within our global crop business, net sales of our insecticides group were up approximately 15% to end at $35,847, as compared to $31,048 during the third quarter of 2018. Within this category, net sales of our granular insecticides were up approximately 8% due to strong demand for Aztec (corn soil insecticide), Counter (nematode control in corn and sugar beets), and Bidrin (a foliar insecticide for cotton), offset by modest declines in Thimet (for domestic sugarcane) and both Mocap and Nemacur (largely in our international markets).

Within the group of herbicides/fungicides/fumigants used in global crop applications, net sales for the third quarter of 2019 increased by approximately 12% to $46,772 from $41,882 in the comparable period of 2018. Net sales of our herbicide products increased approximately 18%, with sales of our Dacthal® herbicide (that is used on a wide variety of high-valued vegetable crops) relatively flat, our Paraquat burn-down product sales increased, and we also enjoyed incremental sales as a result of three newly acquired Raymat products, which were partially offset by lower sales of our bromacil products due to a supply shortage. In global fungicides, we posted significantly higher sales of Equus despite abnormally high in-channel supply, as a result of pre-tariff importation of large quantities by many competitive sellers. Global soil fumigant sales were relatively flat in the quarter.

Within the group of other products (which includes distribution of certain third party products in Central and South America, plant growth regulators, molluscicides and tolling activity), net sales increased 2%, to $22,887, as compared to $22,424 in the third quarter of 2018. Quarterly sales were impacted by substantially reduced demand for our Folex® cotton defoliant due to natural defoliation that occurred as a result of extremely hot and dry weather in the Southeast and Mid-south regions of the United States. However, this decline was more than offset by the positive incremental sales added to this category by our Defensive and Agrovant distribution businesses in Brazil, our new Australia business and quarter-over-quarter gains in our Central American AgriCenter subsidiary.

Our global non-crop sales ended the third quarter of 2019 up 18% at $19,378, as compared to $16,426, for the same period of the prior year. This result was driven by a strong increase in quarterly sales of our aerially-applied Dibrom mosquito adulticide.

Our cost of sales for the third quarter of 2019 was $77,421 or 62% of sales. This compared to $66,480 or 59% of sales for the same period of 2018. The increase in cost of sales as a percentage of net sales in 2019 was driven by a reduction in factory output as we balanced softer weather driven demand for some products with the drive to reduce inventories during 2019. Furthermore, cost of goods was affected by a change in product mix, including the effect of acquired products and distribution businesses, which drive high sales at comparatively lower margins than our pre-existing business.

Gross profit for the third quarter of 2019 increased by $2,163, or 5%, to end at $47,463, as compared to $45,300 for the third quarter of 2018. Gross margin percentage ended at 38% in the three months ended September 30, 2019, as compared to 41% in the same period of the prior year. As previously noted, the change in performance is largely driven by decisions made to manage factory output and inventory levels and the significant growth of our international businesses including those acquired in late 2018 and early in 2019.

As discussed below in detail by department, operating expenses increased by $7,042 (or 21%) to $40,677 for the three months ended September 30, 2019, as compared to the same period in 2018. The differences in operating expenses by department are as follows:

2019 2018 Change % Change
Selling $11,961 $9,637 $2,324 24%
General and administrative 13,406 8,686 4,720 54%
Research, product development and regulatory 5,417 5,895 (478) -8%
Freight, delivery and warehousing 9,893 9,417 476 5%
$40,677 $33,635 $7,042 21%
  • Selling expenses increased by $2,324 to end at $11,961 for the three months ended September 30, 2019, as compared to the same period of 2018. The main drivers were increased promotional expenses directed at domestic markets and the addition of costs associated with the newly acquired products and distribution businesses.
  • General and administrative expenses increased by $4,720 to end at $13,406 for the three months ended September 30, 2019, as compared to the same period of 2018. The increase was driven primarily by the quarterly reassessment of fair value associated with the reduction of deferred consideration for newly acquired businesses in the amount of $651, as compared to $3,969 in prior year and the increase in activities of businesses acquired at the end of 2018 and the beginning of 2019. These increases were partially offset by a decrease in legal costs of approximately $650.
  • Research, product development costs and regulatory expenses decreased by $478 to end at $5,417 for the three months ended September 30, 2019, as compared to the same period of 2018. The decrease relates largely to the timing of regulatory studies necessary to defend our portfolio of products.
  • Freight, delivery and warehousing costs for the three months ended September 30, 2019 were $9,893 or 8.8% of sales as compared to $9,417 or 8.4% of sales for the same period in 2018. As a percentage of sales, freight costs have remained flat, as compared to prior year.

Interest costs net of capitalized interest, were $2,070 in the three months ended September 30, 2019, as compared to $1,116 in the same period of 2018. Average indebtedness and interest costs are summarized in the following table:

Three months ended September 30, 2019 Average Debt Interest Expense Interest Rate Three months ended September 30, 2018 Average Debt Interest Expense Interest Rate
Revolving line of credit (average) $178,886 $2,045 4.6% $80,001 $822 4.1%
Amortization of deferred loan fees — 58 — — 60 —
Amortization of other deferred liabilities — 41 — — 107 —
Other interest (income) expense — 32 — — 146 —
Subtotal 178,886 2,176 4.9% 80,001 1,135 5.7%
Capitalized interest — (106) — — (19) —
Total $178,886 $2,070 4.6% $80,001 $1,116 5.6%

24

The Company’s average overall debt for the three months ended September 30, 2019 was $178,886, as compared to $80,001 for the three months ended September 30, 2018. This increase arose primarily from borrowing activity required to fund acquisitions completed during the fall of 2018 and year to date in 2019. As can be seen from the table above, our effective bank interest rate on our revolving line of credit was 4.6% for the three months ended September 30, 2019, as compared to 5.6% in 2018.

Income tax expense decreased by $2,052 to end at an expense of $1,474 for the three months ended September 30, 2019, as compared to $3,526 for the comparable period in 2018. The effective tax rate for the quarter was 31.3%, as compared to 33.4% in the same period of the prior year. Our effective tax rate for 2018 included a one-time adjustment related to the implementation of the 2017 transition tax in the amount of $1,089. Excluding this one-time expense, the underlying effective tax rate for the quarter was 23.1%. The increase in effective tax rate is primarily driven by the mix of our domestic and international income. Furthermore, the effective tax rate for all interim periods is based on the projected income for the full year and is subject to ongoing review and adjustment by management.

During the three months ended September 30, 2019 and 2018, we recognized losses of $89 and $181, respectively, on our investment in the Hong Kong joint venture, which is a 50% owned equity investment. Furthermore, during the three months ended September 30, 2018, we recognized a loss of $352 on our investment in TyraTech, which became a wholly owned and consolidated subsidiary on November 9, 2018.

Non-controlling interest represents the share of net income or loss that is attributable to the minority stockholder of our majority owned subsidiary, Envance. During the three months ended September 30, 2018, a loss of $35 was attributed to non-controlling interest. Envance became a wholly owned subsidiary on November 9, 2018.

Our net income for the three months ended September 30, 2019 was $3,153 or $0.11 per basic and diluted share, as compared to $6,525 or $0.22 per basic and diluted share in the same period of 2018.

Nine Months Ended September 30 2019 and 2018:

Broadly speaking, the Company’s financial performance for the nine-month period ended September 30, 2019 was characterized by modest growth, on an overall basis, and reduced profitability, as compared to the same period in 2018. Net sales increased by 5%, due entirely to the expansion of our international business, which showed an 18% increase in net sales and a 29% increase in gross profit, partially offset by a decline in the US business, which recorded a 3% decrease in net sales and an 8% decrease in gross profit. Further, for the first nine months of 2019, international sales constituted 41% of overall sales, up from 36% for the same period in 2018. Growth in Central America, Brazil, and in Canada, where we sell our recently acquired Assure II fungicide, set the pace for international growth during the period. Domestically, sales were constrained by wet and cold conditions throughout the US during the first and second quarters; these conditions reduced demand not only during the planting season, but also in the aftermath, at which time soil fumigant and burn-down herbicide use was limited. In addition, exceptional heat and dryness during the third quarter reduced the need for our cotton defoliant, Folex in the Southern region.

Gross margin decreased by 1% during the first nine months of 2019 as a result of the strong growth of our international sales, which are generally at lower margins when compared to our US business, and by decisions taken to hold down factory output in order to drive down inventory levels during 2019. Operating expenses during the nine-month period increased primarily as a result of the addition of products and businesses acquired in late 2018 and year to date in 2019, including reductions to deferred liabilities for purchase consideration which were lower in 2019, as compared to 2018. Further, we recorded higher interest expense arising from borrowings due largely to acquisition activity in 2018 and 2019. These factors, together, resulted in a decrease in net income for the first nine months of the year. A more detailed explanation of net sales, markets and factors affecting profitability appears below.

The Company’s overall operating results for the first nine months of 2019 were mixed, as compared to those of the same period of 2018. Net sales for the first nine months of 2019 were up 5% ($337,664 vs. $322,934), gross profit was essentially flat ($130,818 vs. $129,648), and gross margin declined to 39% from 40% of net sales. Operating expenses rose by approximately 9% ($110,839 vs. $102,011) and increased as a percent of net sales to 33% from 32%. Net income attributable to American Vanguard was down 39% ($10,165 vs. $16,779).

The Company’s overview of sales and gross margin performance for the nine months ended September 30, 2019 and 2018 is as follows:

Net sales: For the nine months ended September 30, 2019 2018 Change % Change
US crop $152,512 $166,397 $(13,885) -8%
US non-crop 47,543 39,492 8,051 20%
US total 200,055 205,889 (5,834) -3%
International 137,609 117,045 20,564 18%
Net sales: $337,664 $322,934 $14,730 5%
Gross profit:
US crop $66,140 $78,439 $(12,299) -16%
US non-crop 24,363 19,843 4,520 23%
US total 90,503 98,282 (7,779) -8%
International 40,315 31,366 8,949 29%
Total gross profit: $130,818 $129,648 $1,170 1%
Gross margin domestic 45% 48%
Gross margin international 29% 27%
Gross margin total 39% 40%

Our US crop business recorded net sales that were about 8% below those of the first nine months of 2018 ($152,512 vs. $166,397). Insecticides sales were down period-over-period with strong demand for our Aztec (corn insecticide), Counter (nematicide) and Bidrin cotton products offset by decreased sales of Thimet, largely attributable to unfavorable weather conditions in the Midwest and Southeast regions of the United States. With respect to herbicides, Dacthal sales improved, while Impact was stable period-over-period. Further, Parazone sales were down due to persistent wet weather in several key markets and higher than normal competitor inventory. Soil fumigant sales were down slightly in the first nine months this year due to wet weather in critical geographic regions that inhibited application of this liquid product. Fungicide sales were down due to an oversupply of Chinese-produced chlorothalonil arising from expedited purchases made by companies within our sector in order to minimize tariffs. Among growth regulators, we experienced a significant drop in demand for our Folex cotton harvest defoliant attributable to the natural defoliation that occurred in the southern United States, as the result of extreme hot and dry weather.

Net sales of our domestic non-crop business increased about 20% to $47,543 from $39,492, during the first nine months of 2019. This result was due largely to continued strong demand for our Dibrom® mosquito control adulticide (as applicators restocked this premium product), increased demand for our pest strips and from our Envance Technologies business.

Net sales of our international businesses were up approximately 18% during the period ($137,609 vs. $117,045). A significant part of this increase was due to the addition of sales from our newly acquired Brazilian subsidiaries, Defensive and Agrovant, our Australian acquisition, and the addition of our Assure II herbicide products that were acquired in December 2018. Additionally, we experienced improved sales performance from AgriCenter in Central America, with higher granular soil insecticide sales, steady demand for fungicides and miscellaneous products, and somewhat lower foliar insecticide sales. Elsewhere in the international sector, we posted reduced sales of our insecticides Mocap, Nemacur, Counter and Thimet, while bromacil sales were up slightly. A more detailed explanation of net sales, markets and factors affecting profitability appears below.

Nine Months Ended September 30, 2019 and 2018:

Net sales: 2019 2018 Change % Change
Insecticides $112,539 $115,702 $(3,163) -3%
Herbicides/soil fumigants/fungicides 115,510 113,144 2,366 2%
Other, including plant growth regulators 60,730 52,269 8,461 16%
Total crop 288,779 281,115 7,664 3%
Non-crop 48,885 41,819 7,066 17%
Total net sales $337,664 $322,934 $14,730 5%
Cost of sales:
Insecticides $68,401 $73,441 $(5,040) -7%
Herbicides/soil fumigants/fungicides 72,478 66,990 5,488 8%
Other, including plant growth regulators 42,044 31,459 10,585 34%
Total crop 182,923 171,890 11,033 6%
Non-crop 23,923 21,396 2,527 12%
Total cost of sales $206,846 $193,286 $13,560 7%
Gross profit:
Insecticides $44,138 $42,261 $1,877 4%
Herbicides/soil fumigants/fungicides 43,032 46,154 (3,122) -7%
Other, including plant growth regulators 18,686 20,810 (2,124) -10%
Gross profit crop 105,856 109,225 (3,369) -3%
Gross profit non-crop 24,962 20,423 4,539 22%
Total gross profit $130,818 $129,648 $1,170 1%
Gross margin crop 37% 39%
Gross margin non-crop 51% 49%
Total gross margin 39% 40%
Net sales: 2019 2018 Change % Change
US $200,055 $205,889 $(5,834) -3%
International 137,609 117,045 20,564 18%
Total net sales $337,664 $322,934 $14,730 5%

Across our global crop business, net sales of our insecticides group declined approximately 3% to end at $112,539, as compared to $115,702 during the nine months ended September 30, 2018. Within this category, net sales of our non-granular insecticides were driven by our cotton insecticide Bidrin®, which posted approximately a 50% sales gain due to increased cotton acres in 2019, as compared to the prior year. This increase more than offset sales declines of Abamectin resulting from regional weather issues and bifenthrin resulting from generic competitive pressures. Despite a 36% increase in net sales of our Aztec corn soil insecticide, granular soil insecticides were down about 9% due to lower Thimet sales in peanuts, lower sales of Counter in sugar beets, and lower sales internationally for Mocap and Nemacur, in part due to regulatory application limitations.

Within the group of herbicides/fungicides/fumigants used in global crop applications, net sales for the nine months ended September 30, 2019 increased by approximately 2% to $115,510 from $113,144, in the comparable period of 2018. While our Impact and Dacthal products continued to deliver strong and stable results, we experienced reduced sales of our chlorothalonil fungicide Equus due to abnormally high supply (from expedited, pre-tariff importation of large quantities by many sellers) and pricing pressure in the face of seasonally normal demand. Additionally, wet weather inhibited the application of our Parazone burn-down herbicide and Metam soil fumigants. Offsetting these declines were the addition of the Assure II herbicide acquired at the end of 2018 and a significant period-over-period increase in our bromacil herbicides; both of these factors impacted our international business performance for the period.

Within the group of other products (which includes distribution of certain third party products particularly in Central and South America, plant growth regulators, molluscicides and tolling activity), net sales were $60,730, up approximately 16%, as compared to $52,269 in the first nine months of 2018. This result benefitted from the inclusion of the Brazilian and Australian businesses, increased sales in the AgriCenter business and improved sales of our growth regulator NAA. These items were partially offset by significantly lower sales of our Folex® cotton defoliant resulting from extreme hot and dry weather in the southern United States during the cotton harvest season.

Our non-crop sales ended the first nine months of 2019 with net sales of $48,885 up 17%, as compared to $41,819 for the same period of the prior year. This category benefitted from continued strong sales of our aerially-applied mosquito adulticide Dibrom, commercial pest control products including pest strips, and our pharmaceutical products.

International sales for the first nine months ended at $137,609, an 18% increase over the $117,045 in the same period of 2018. The main driver of this performance was the addition of the Defensive and Agrovant businesses in Brazil, the new Australian business, continuing growth of the AgriCenter Central American business, and the acquisition of the Assure II products at the end of 2018. Our traditional product portfolio (including Mocap, Nemacur) showed significant year-to-date sales declines resulting from various weather-related and regulatory influences.

Our cost of sales for the first nine months ended September 30, 2019 is $206,846 or 61% of net sales. This compares to $193,286 or 60% of net sales in the same period of 2018. The increase in cost of sales as a percentage of net sales in 2019 was driven in part by decisions made to reduce factory output as part of our 2019 manufacturing plan.

Gross profit for the nine months ended September 30, 2019 increased by $1,170 to end at $130,818, as compared to $129,648 for the first nine months of 2018. Gross margin percentage ended at 39% in the first nine months of 2019, as compared to 40% in the same period of the prior year. As previously noted, the change in performance is largely driven by the Company manufacturing plan for 2019, which responds to the weather related lower sales already discussed and the new businesses acquired in early 2019.

Operating expenses increased by $8,828 to $110,839 for the nine months ended September 30, 2019, as compared to the same period in 2018. The changes in operating expenses by department are as follows:

2019 2018 Change % Change
Selling $34,646 $29,617 $5,029 17%
General and administrative 33,890 29,410 4,480 15%
Research, product development and regulatory 17,956 19,458 (1,502) -8%
Freight, delivery and warehousing 24,347 23,526 821 3%
$110,839 $102,011 $8,828 9%
  • Selling expenses increased by $5,029 to end at $34,646 for the nine months ended September 30, 2019, as compared to the same period of 2018. The main drivers were an increase in activities from the products and businesses acquired during the end of 2018 and during the first nine months of 2019, and increased advertising and marketing activities in both our domestic and international regions.
  • General and administrative expenses increased by $4,480 to end at $33,890 for the nine months ended September 30, 2019, as compared to the same period of 2018. The increase was driven by the administrative expenses associated with the activities of the newly acquired businesses and the reassessment of the fair value related to deferred consideration for the acquired businesses in the amount of $3,539, as compared to $5,437 in prior year. These increases were partially offset by decreases in legal costs of approximately $1,664.
  • Research, product development costs and regulatory expenses decreased by $1,502 to end at $17,956 for the nine months ended September 30, 2019, as compared to the same period of 2018. The main drivers for the decrease were timings related to third party product defense studies which are running later in 2019 than in the prior year, and lower business development expenses as we have reached the commercialization phase of a key part of our SIMPAS project.
  • Freight, delivery and warehousing costs for the nine months ended September 30, 2019 were $24,347 or 7.2% of sales as compared to $23,526 or 7.3% of sales for the same period in 2018.

Interest costs net of capitalized interest were $5,606 in the first nine months of 2019, as compared to $2,961 in the same period of 2018. Average indebtedness and interest costs are summarized in the following table:

Nine months ended September 30, 2019 Average Debt Interest Expense Interest Rate Nine months ended September 30, 2018 Average Debt Interest Expense Interest Rate
Revolving line of credit (average) $166,877 $5,530 4.4% $92,971 $2,399 3.4%
Amortization of deferred loan fees — 161 — — 177 —
Amortization of other deferred liabilities — 41 — — 261 —
Other interest (income) expense — 102 — — 178 —
Subtotal 166,877 5,834 4.7% 92,971 3,015 4.3%
Capitalized interest — (228) — — (54) —
Total $166,877 $5,606 4.5% $92,971 $2,961 4.2%

The Company’s average overall debt for the nine months ended September 30, 2019 was $166,877, as compared to $92,971 for the nine months ended September 30, 2018. The difference in average debt levels between the two periods relates to the businesses acquired during the final quarter of 2018 and year-to-date in 2019. As can be seen from the table above, our effective bank interest rate on our revolving line of credit was 4.5% for the nine months ended September 30, 2019, as compared to 4.2% in 2018.

Income tax expense was $4,059 for the nine months ended September 30, 2019, as compared to $6,966 for the nine months ended September 30, 2018. The effective tax rate for the nine months ended September 30, 2019 and 2018 was 28.2%. As with the quarter ended September 30, 2018, the nine month period is impacted by the transition tax adjustment of $1,089. Excluding that one-time charge, the Company’s tax rate would have been 23.8% for the nine months ended September 30, 2018. The effective tax rate is based on the projected income for the full year and is subject to ongoing review and adjustment by management.

During the nine months ended September 30, 2019 and 2018, the Company recognized losses of $149 and $256, respectively, on our investment in the Hong Kong joint venture which is a 50% owned equity investment. During the nine months ended September 30, 2018, we recognized a loss of $795 on our investment in TyraTech. TyraTech became a wholly owned and consolidated subsidiary on November 9, 2018.

Non-controlling interest represents the share of net income or loss that is attributable to the minority stockholder of our majority owned subsidiary, Envance. During the nine months ended September 30, 2018, a loss of $120 attributed to non-controlling interest. Envance became a wholly owned subsidiary on November 9, 2018.

Net income for the nine months ended September 30, 2019 was $10,165 or $0.35 per basic and $0.34 per diluted share, as compared to $16,779 or $0.57 per basic and $0.56 per diluted share in the same period of 2018.

LIQUIDITY AND CAPITAL RESOURCES

The Company used cash of $21,684 in operating activities during the nine months ended September 30, 2019, as compared to $15,090 during the nine months ended September 30, 2018. Included in the $21,684 are net income of $10,165, plus non-cash depreciation, amortization of intangibles and other assets and discounted future liabilities, in the amount of $17,107, provision for bad debts in the amount of $728, reassessment of deferred compensation of $3,539, stock based compensation of $5,159, changes in deferred income taxes of $459 and losses from equity method investments of $149. The total provided net cash inflows of $29,310, as compared to $35,191 for the same period of 2018.

As of September 30, 2019, the Company increased working capital by $49,160, as compared to working capital at December 31, 2018. Inventories increased by $19,713, driven by our expanded businesses. Deferred revenue decreased by $19,800, driven by customer decisions regarding product demand, payment timing and our cash incentive programs. Our accounts payable balances increased by $5,516 driven by increased manufacturing activity and the impact of newly acquired businesses. Accounts receivables increased by $15,983 driven primarily by a different mix of domestic crop sales (and associated timing and terms) following the purchases of new products in 2018. Prepaid expenses increased by $849 and income tax payable increased by $4,477. Accrued programs increased by $20,163. Finally, other payables and accrued expenses decreased by $4,936.

With regard to our program accrual, the change primarily reflects our mix of sales and customers in the first nine months of 2019, as compared to the prior year. The Company accrues programs in line with the growing season upon which specific products are targeted. Most of our programs relate to domestic products. Typically, domestic crops have a growing season that ends on September 30th of each year. During the first nine months of 2019, the Company made accruals for programs in the amount of $38,900 and made payments in the amount of $18,737. During the first nine months of 2018, the Company made accruals in the amount of $38,027 and made payments in the amount of $15,145.

Cash used for investing activities was $42,382 for the nine months ended September 30, 2019, as compared to $6,788 for the nine months ended September 30, 2018. The Company spent $10,546 on capital expenditures primarily focused on continuing to invest in manufacturing infrastructure and $31,836 relating to products and business acquisitions during 2019.

The Company has a revolving line of credit that is shown as long-term debt in the condensed consolidated balance sheets at September 30, 2019 and December 31, 2018. The debt is summarized in the following table:

Long-term indebtedness ($000's) September 30, 2019 December 31, 2018
Revolving line of credit $165,600 $97,400
Deferred loan fees (592) (729)
Net long-term debt $165,008 $96,671

As of June 30, 2017, AMVAC Chemical Corporation (“AMVAC”), the Company’s principal operating subsidiary, as borrower, and affiliates (including the Company, AMVAC CV and AMVAC BV), as guarantors and/or borrowers, entered into a Third Amendment to Second Amended and Restated Credit Agreement (the “Credit Agreement”) with a group of commercial lenders led by Bank of the West (AMVAC’s primary bank) as agent, swing line lender and Letter of Credit (“L/C”) issuer. The Credit Agreement is a senior secured lending facility, consisting of a line of credit of up to $250,000, an accordion feature of up to $100,000 and a maturity date of June 30, 2022. The Credit Agreement contains two key financial covenants; namely, borrowers are required to maintain a Consolidated Funded Debt Ratio of no more than 3.25-to-1 and a Consolidated Fixed Charge Covenant Ratio of at least 1.25-to-1. The Company’s borrowing capacity varies with its financial performance, measured in terms of EBITDA, for the trailing twelve month period. Under the Credit Agreement, revolving loans bear interest at a variable rate based, at borrower’s election with proper notice, on either (i) LIBOR plus the “Applicable Rate” which is based upon the Consolidated Funded Debt Ratio (“Eurocurrency Rate Loan”) or (ii) the greater of (x) the Prime Rate, (y) the Federal Funds Rate plus 0.5%, and (z) the Daily One-Month LIBOR Rate plus 1.00%, plus, in the case of (x), (y) or (z) the Applicable Rate (“Alternate Base Rate Loan”). Interest payments for Eurocurrency Rate Loans are payable on the last day of each interest period (either one, two, three or six months, as selected by the borrower) and the maturity date, while interest payments for Alternate Base Rate Loans are payable on the last business day of each month and the maturity date.

At September 30, 2019, according to the terms of the Credit Agreement and based on its performance against the most restrictive covenants listed above, the Company had the capacity to increase its borrowings by up to $30,435. This compares to an available borrowing capacity of $105,111 as of September 30, 2018. The level of borrowing capacity is driven by three factors: (1) our financial performance, as measured in EBITDA for trailing twelve month period, which has declined, (2) net borrowings, which have increased due to recent acquisitions, and (3) the leverage covenant (being the number of times EBITDA the Company may borrow under its credit facility agreement).

We believe that anticipated cash flow from operations, existing cash balances and available borrowings under our senior credit facility will be sufficient to provide us with liquidity necessary to fund our working capital and cash requirements for the next twelve months.

RECENTLY ISSUED ACCOUNTING GUIDANCE

Please refer to Note 15 in the accompanying Notes to the Condensed Consolidated Financial Statements for recently issued accounting standards.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The Company continually re-assesses the critical accounting policies used in preparing its financial statements. In the Company’s Form 10-K filed with the SEC for the year ended December 31, 2018, the Company provided a comprehensive statement of critical accounting policies. These policies have been reviewed in detail as part of the preparation work for this Form 10-Q. After our review of these matters, we have determined that, during the subject reporting period, there has been no material change to the critical accounting policies that are listed in the Company’s Form 10-K for the year ended December 31, 2018, except for the adoption of ASC 842, Leases, as of January 1, 2019.

Certain of the Company’s policies require the application of judgment by management in selecting the appropriate assumptions for calculating financial estimates. These judgments are based on historical experience, terms of existing contracts, commonly accepted industry practices and other assumptions that the Company believes are reasonable under the circumstances. These estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the condensed consolidated financial statements in the period that revisions are determined to be necessary. Actual results may differ from these estimates under different outcomes or conditions.

Market risk

As filed, 1,251 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The Company is exposed to market risk related to changes in interest rates, primarily from its borrowing activities. The Company’s indebtedness to its primary lender is evidenced by a line of credit with a variable rate of interest, which fluctuates with changes in the lender’s reference rate. For more information, please refer to the applicable disclosures in the Company’s Form 10-K filed with the SEC for the year ended December 31, 2018.

The Company conducts business in various foreign currencies, primarily in Europe, Mexico, Central and South America. Therefore, changes in the value of the currencies of such countries or regions affect the Company’s financial position and cash flows when translated into US dollars. The Company has mitigated and will continue to mitigate a portion of its currency exchange exposure through natural hedges based on the operation of decentralized foreign operating companies in which the majority of all costs are local currency based. Furthermore, the Company has established a procedure for covering forward exchange rates on specific purchase orders when appropriate. A 10% change in the value of all foreign currencies would have an immaterial effect on the Company’s financial position and cash flows.

Controls and procedures

As filed, 1,261 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

As of September 30, 2019, the Company has a comprehensive set of disclosure controls and procedures designed to ensure that all information required to be disclosed in our filings under the Securities Exchange Act (1934) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. As of September 30, 2019, the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, has concluded, based on their evaluation, that the Company’s disclosure controls and procedures are effective to provide reasonable assurance of the achievement of the objectives described above.

There were no changes in the Company’s internal controls over financial reporting that occurred during the most recent quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting. We implemented internal controls to ensure we adequately evaluated our contracts and properly assessed the impact of the new accounting standards under ASC 842, Leases.

PART II. OTHER INFORMATION

(Dollars in thousands)

The Company was not required to report any matters or changes for any items of Part II except as disclosed below.

Risk factors

As filed, 298 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The Company continually re-assesses the business risks, and as part of that process detailed a range of risk factors in the disclosures in American Vanguard’s Report on Form 10-K for the fiscal year ended December 31, 2018 as well as the Company’s Form 10-Q for the period ended September 30, 2019.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2019-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2019-07-01 to 2019-09-30$124.9mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2019-01-01 to 2019-09-30$337.7mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2019-07-01 to 2019-09-30$77.4mus-gaap:CostOfRevenue
Cost of revenue9 months2019-01-01 to 2019-09-30$206.8mus-gaap:CostOfRevenue
Gross profit3 months2019-07-01 to 2019-09-30$47.5mus-gaap:GrossProfit
Gross profit9 months2019-01-01 to 2019-09-30$130.8mus-gaap:GrossProfit
Operating income3 months2019-07-01 to 2019-09-30$6.8mus-gaap:OperatingIncomeLoss
Operating income9 months2019-01-01 to 2019-09-30$20.0mus-gaap:OperatingIncomeLoss
Interest expense3 months2019-07-01 to 2019-09-30$2.1mus-gaap:InterestExpense
Interest expense9 months2019-01-01 to 2019-09-30$5.6mus-gaap:InterestExpense
Income tax3 months2019-07-01 to 2019-09-30$1.5mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2019-01-01 to 2019-09-30$4.1mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2019-07-01 to 2019-09-30$3.2mus-gaap:NetIncomeLoss
Net income9 months2019-01-01 to 2019-09-30$10.2mus-gaap:NetIncomeLoss
Diluted EPS3 months2019-07-01 to 2019-09-30$0.11us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2019-01-01 to 2019-09-30$0.34us-gaap:EarningsPerShareDiluted
Basic EPS3 months2019-07-01 to 2019-09-30$0.11us-gaap:EarningsPerShareBasic
Basic EPS9 months2019-01-01 to 2019-09-30$0.35us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2019-07-01 to 2019-09-3029,650,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2019-01-01 to 2019-09-3029,591,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2019-01-01 to 2019-09-30−$21.7mus-gaap:NetCashProvidedByUsedInOperatingActivities
Dividends paid9 months2019-01-01 to 2019-09-30$1.7mus-gaap:PaymentsOfDividends
Share repurchases9 months2019-01-01 to 2019-09-30$2.6mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2019-09-30$5.9mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2019-09-30$357.0mus-gaap:AssetsCurrent
Total assetsAt period end2019-09-30$681.3mus-gaap:Assets
Current liabilitiesAt period end2019-09-30$143.2mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2019-09-30$343.3mus-gaap:Liabilities
Long-term debtAt period end2019-09-30$165.0mus-gaap:LongTermDebtNoncurrent
Short-term borrowingsAt period end2019-09-30$0us-gaap:ShortTermBorrowings
Shareholders' equityAt period end2019-09-30$338.0mus-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Source: SEC EDGAR, the filing index for accession 0001564590-19-041104. Last ingested by Listed: Nov 11, 2026, 00:16 ET. Listed shows no prices and gives no investment advice.